Evidence map›Paper›PMID 33257091›Full record

ArticleClinical therapeutics2020

Comorbidities, Age, and Polypharmacy Limit the Use by US Older Adults with Nocturia of the Only FDA-approved Drugs for the Symptom.

Kara Suvada, Laura Plantinga, Camille P Vaughan, Alayne D Markland, Anna Mirk, Kathryn L Burgio, Susanne M Erni, Mohammed K Ali, Ike Okosun, Henry Young and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Kara SuvadaDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA; Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Laura PlantingaDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA; Division of Geriatrics and Gerontology, Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA.
Camille P VaughanDivision of Geriatrics and Gerontology, Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA; Birmingham/Atlanta Geriatric Research, Education, and Clinical Center, Brookhaven, GA, USA.
Alayne D MarklandBirmingham/Atlanta Geriatric Research, Education, and Clinical Center, Birmingham, AL, USA; Division of Gerontology, Geriatrics and Palliative Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Anna MirkDivision of Geriatrics and Gerontology, Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA; Birmingham/Atlanta Geriatric Research, Education, and Clinical Center, Brookhaven, GA, USA.
Kathryn L BurgioBirmingham/Atlanta Geriatric Research, Education, and Clinical Center, Birmingham, AL, USA; Division of Gerontology, Geriatrics and Palliative Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Susanne M ErniDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Mohammed K AliDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA; Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA; Department of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, GA, USA.
Ike OkosunDepartment of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, GA, USA.
Henry YoungCollege of Pharmacy, University of Georgia, Athens, GA, USA.
Patricia S GoodeBirmingham/Atlanta Geriatric Research, Education, and Clinical Center, Birmingham, AL, USA; Division of Gerontology, Geriatrics and Palliative Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Theodore M JohnsonDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA; Birmingham/Atlanta Geriatric Research, Education, and Clinical Center, Brookhaven, GA, USA; Department of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, GA, USA; Division of General Internal Medicine, Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA. Electronic address: tmjohns@emory.edu.
Emory University · USUniversity of Alabama at Birmingham · USGeorgia State University · USUniversity of Georgia · US

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Coexisting nocturia and insomnia in older adults: Planning a trial of integrated therapyR34AG058835 · NIA · EMORY UNIVERSITY · PI FUNG, CONSTANCE, MARKLAND, ALAYNE DENISE · 2019 to 2021
$683k
NCATS NIH HHS UL1 TR002378NIA NIH HHS R34 AG058835
6 · The paper itself

Abstract

purposeThe goal of this study was to determine if the US adult population with nocturia (waking from sleep at night to void) can easily take medications (desmopressin acetate) approved by the US Food and Drug Administration for nocturia. The study examined: (1) the prevalence of comorbid conditions, laboratory abnormalities, and concomitant medications that increase risk of desmopressin use; and (2) whether these factors are associated with age or nocturia frequency.

methodsUsing a cross-sectional analysis of four US National Health and Nutrition Examination Survey (NHANES) waves (2005-2012), a total of 4111 participants aged ≥50 years who reported ≥2 nightly episodes of nocturia were identified. The main outcome was frequency of contraindications and drug interactions as described in US Food and Drug Administration-approved prescribing information. These prescribing concerns were matched to examination findings, medical conditions, concomitant medications, and laboratory results of NHANES participants. The associations between prescribing concerns and nocturia severity and age groups were examined.

findingsThe mean participant age was 65.7 years (95% CI, 65.3-66.1), and 45.5% were male. Desmopressin prescribing concerns were present in 80.5% (95% CI, 78.0-82.9) of those ≥50 years of age with nocturia; 50.0% (95% CI, 47.0-53.0) had contraindications, and 41.6% (95% CI, 39.3-44.0) took a concomitant drug that could increase risk of low serum sodium. Desmopressin contraindications were higher with older age (P < 0.001) and present in 73.2% (95% CI, 69.3-77.1) of those ≥80 years of age. IMPLICATIONS: Using NHANES data, this study showed that older US adults with nocturia have a high prevalence of medical conditions, concomitant medications, and baseline laboratory abnormalities that likely increase the risk of potentially severe adverse side effects from desmopressin use. A medication designed and approved for a clinical symptom that is most common in older adults could not be taken by most of the older adults with the symptom.

Indexed as

AgedAged, 80 and overAntidiuretic AgentsComorbidityDeamino Arginine VasopressinDrug ApprovalDrug InteractionsFemaleHumansMaleMiddle AgedNocturiaNutrition SurveysPolypharmacyUnited StatesUnited States Food and Drug AdministrationAntidiuretic AgentsDeamino Arginine Vasopressinaged or elderlycomorbiditymedicationspolypharmacyrisk factorssafety

Identifiers

PMID33257091
PMCPMC8811749
OpenAlexW3108634531

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.